Theravance Biopharma

Theravance Biopharma said the phase‑3 CYPRESS study of ampreloxetin missed its primary endpoint, prompting the company to discontinue the program. The stock then plunged about 29%. A strategic review committee is expediting alternatives to boost shareholder value, including a possible sale, and is working with Lazard. Theravance also announced a restructuring that will affect roughly 50% of its workforce and aims for annual cost savings of about $70 million (around 60%); the company expects an annualized cash flow of $60–70 million starting in Q3 2026. » Más en de.investing.com

The shares of Theravance Biopharma marked a new 52-week high at $21.01 and are up about 117.63% year-to-date (six months: +81.39%), with a market capitalization of roughly $1.06 billion. The company reported an unexpected Q3 2025 earnings per share of $0.07 (expected: -$0.13) and a 19% increase in collaboration revenues to $20 million. Analysts see further upside: Oppenheimer rates Theravance “Outperform” with a $27 price target and cites the phase‑3 results for ampreloxetin (Q1 2026) as an important catalyst. Despite strong balance-sheet metrics (current ratio 9.48), InvestingPro currently values the stock above its fair value but gives a very good overall assessment of the financial position. » Más en de.investing.com

Theravance Biopharma stock climbed to a 52-week high of $20.69 after rising 138.34% over the past year. InvestingPro cites a very good Financial Health Score of 3.52, a market capitalization of about $1.05 billion, revenue growth of 27.12% and a current ratio of 9.48. Q3/2025 delivered EPS of $0.07 (expected -$0.13) and collaboration revenues rose 19% to $20 million; Oppenheimer rates the stock "Outperform" with a $27 price target, naming ampreloxetin as the key driver with a 50% probability of success for the upcoming phase 3 study. » Más en de.investing.com

Theravance Biopharma’s stock rose to a new 52‑week high of $20.29, up 118.59% over the past year and 112% year‑to‑date, with a market capitalization of about $1.02 billion. The company reported Q3/2025 earnings per share of $0.07 versus expected -$0.13 and revenue growth of 27.12% over the last twelve months; collaboration revenues increased 19% to $20 million. Theravance also announced a virtual KOL event on December 8 for the Phase‑3 program of Ampreloxetin; technical indicators reportedly point to an overbought condition for the stock. » Más en de.investing.com

Theravance Biopharma posted earnings per share of $0.07 in Q3/2025 versus an expected -$0.13, significantly beating estimates. Collaboration revenues rose 19% to $20 million, and net sales of UPELRI increased 15% to $71.4 million. The company ended the quarter with $333 million in cash and no debt; the stock rose 2.24% after hours. For Q4/2025, Theravance expects $75 million in milestone payments and is preparing a potential NDA submission for Ampraloxetin; data from the Cypress study are expected in Q1/2026. » Más en de.investing.com